← All Calidi Biotherapeutics, INC filings

Calidi Biotherapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

AMEX
CLDI
Calidi Biotherapeutics, INC
DEFA14A: CALIDI BIOTHERAPEUTICS, INC. Files Definitive Proxy Statement with SEC
CALIDI BIOTHERAPEUTICS, INC. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.
AMEX
CLDI
Calidi Biotherapeutics, INC
DEF: Calidi Biotherapeutics Seeks Stockholder Approval for Reverse Split and Expanded Equity Plan Amidst Ongoing Capital Raises
Calidi Biotherapeutics, Inc. is calling its stockholders to a virtual Annual Meeting on July 9, 2025, to vote on key proposals including a discretionary reverse stock split, an increase in its equity incentive plan shares, and the ratification of its new independent auditor.
AMEX
CLDI
Calidi Biotherapeutics, INC
DEF 14A: Calidi Biotherapeutics Sets Date for Virtual Annual Stockholders Meeting
Calidi Biotherapeutics will hold its annual stockholders meeting virtually on September 20, 2024, to vote on the election of directors and ratification of the appointment of auditors.
AMEX
CLDI
Calidi Biotherapeutics, INC
DEF 14A: Calidi Biotherapeutics Seeks Stockholder Approval for Reverse Stock Split, Convertible Note Conversions, and Equity Purchase Agreement
Calidi Biotherapeutics is holding a special meeting to seek stockholder approval for a reverse stock split, the conversion of convertible notes, and a standby equity purchase agreement to enhance financial flexibility.